PT  - JOURNAL ARTICLE
AU  - Gaetano Perone
TI  - An ARIMA Model to Forecast the Spread and the Final Size of COVID-2019 Epidemic in Italy
AID  - 10.1101/2020.04.27.20081539
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.27.20081539
4099  - http://medrxiv.org/content/early/2020/05/03/2020.04.27.20081539.short
4100  - http://medrxiv.org/content/early/2020/05/03/2020.04.27.20081539.full
AB  - Coronavirus disease (COVID-2019) is a severe ongoing novel pandemic that is spreading quickly across the world. Italy, that is widely considered one of the main epicenters of the pandemic, has registered the highest COVID-2019 death rates and death toll in the world, to the present day. In this article I estimate an autoregressive integrated moving average (ARIMA) model to forecast the epidemic trend over the period after April 4, 2020, by using the Italian epidemiological data at national and regional level. The data refer to the number of daily confirmed cases officially registered by the Italian Ministry of Health (www.salute.gov.it) for the period February 20 to April 4, 2020. The main advantage of this model is that it is easy to manage and fit. Moreover, it may give a first understanding of the basic trends, by suggesting the hypothetic epidemic’s inflection point and final size.Highlights❖ ARIMA models allow in an easy way to investigate COVID-2019 trends, which are nowadays of huge economic and social impact.❖ These data may be used by the health authority to continuously monitor the epidemic and to better allocate the available resources.❖ The results suggest that the epidemic spread inflection point, in term of cumulative cases, will be reached at the end of May.❖ Further useful and more precise forecasting may be provided by updating these data or applying the model to other regions and countries.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe author received no specific funding for this workAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data are available at URL: https://github.com/pcm-dpc/COVID-19/tree/master/dati-regioni. https://github.com/pcm-dpc/COVID-19/tree/master/dati-regioni.